 |
 |
 |
| |
IIBR's
multi-disciplinary protein engineering capabilities are
supported by extensive professional expertise and a full complement
of modern on-site facilities.
Innovative engineered protein and peptide products are
developed using the following capabilities: |
|
| |
Molecular
design |
|
| |
3-D
models of macromolecular structures are constructed using
homology modeling and simulation of molecular properties.
The model lead to prediction of the effects of structural
modifications on biological activity and physicochemical
properties of the engineered products. |
|
| |
Engineering
of Novel Proteins |
|
| |
Site-directed
mutagenesis and other gene manipulation techniques are
employed to engineer the properties predicted by structure-function
analysis into the template sequences. Efficient expression
in eukaryotic/bacterial systems is designed to generate
analytical and preparative amounts of the engineered protein. |
|
| |
Protein
and Peptide Chemistry |
|
| |
Biologically active peptides are obtained through state-of-the-art
high resolution HPLC and solid phase synthesis. Multiple
peptide synthesis, including peptide libraries, is applied
to establish structure-function relationship and generate
tailored analogues. |
|
| |
Chemical
Modification of Engineered Proteins |
|
| |
Optimization of the pharmacokinetic properties of recombinant
proteins of interest is achieved by various chemical modifications
such as polyethylene-glycol (PEG) conjugation. Meticulous
analyses of the chemically modified products are performed
to ensure preservation of bioactivity, reproducibility
of the chemical modification procedure, and maximal homogeneity
of the product. |
|
| |
Manipulation
of Post-Translation Processing |
|
| |
Expressor
cells are tailored for the efficient production of recombinant
proteins displaying improved physicochemical and pharmacokinetic
properties, by the heterologous co-expression of specialized
glycosyltransferases and glycosidases (eg. sialyltransferase),
to support production of glycoproteins displaying optimally
processed oligosaccharides. The biochemical and pharmacological
traits of target macromolecules of interest may be further
improved by altering other post-translation related traits
such as state of assembly, transforming the recombinant
product into highly assembled oligomeric forms. Recombinant
product glycosylation is evaluated by various methods,
including mass spectrometry analysis, to ensure optimal
processing and consistency of recombinant glycoprotein
products. |
|
| |
Customized
Development |
|
| |
The
IIBR protein engineering team has developed various immunomodulators,
synthetic vaccines and enzyme molecules with modified
catalytic characteristics (cholinesterases). Customized
protein derivatives exploiting these interactive processes
are developed by IIBR. |
|
 |
 |
 |
Download this page in PDF format